Palmitoyl Tetrapeptide-7 vs SNAP-8
A side-by-side research comparison of Palmitoyl Tetrapeptide-7 and SNAP-8 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Palmitoyl Tetrapeptide-7 | SNAP-8 |
|---|---|---|
| Full name | Palmitoyl Tetrapeptide-7 (Pal-GQPR) | SNAP-8 (Acetyl Octapeptide-3) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Inhibits IL-6 release from keratinocytes and reduces inflammation-mediated MMP activation, preserving existing collagen while complementing Pal-GHK collagen building. | More effectively competes with SNAP-25 for SNARE complex incorporation due to longer sequence, providing greater vesicle-membrane fusion inhibition. |
| Molecular weight | 693 Da | 1,075 Da |
| Half-life | 8-12 hours (topical) | 8-14 hours (topical) |
| Bioavailability | Good (topical) | Moderate (topical) |
| Typical dose | 2-4% in formulation | 3-10% solution |
| Frequency | 1-2x daily | 2x daily |
| Route | Topical | Topical |
Palmitoyl Tetrapeptide-7 reported benefits
- Anti-inflammatory (skin)
- Reduces IL-6
- Prevents collagen degradation
- Combats inflammaging
SNAP-8 reported benefits
- Superior to argireline
- Deeper wrinkle reduction
- Prevents expression lines
- Good skin penetration
Related comparisons
Research and educational reference only. Not medical advice.